It is trading at $4.10 well below the 50 day moving average which is $5.18 and which is quite a bit lower than the 200 …
The stock’s market capitalization is 346.64M, it has a 52-week low of 3.75 and a 52-week high of 9.25. The share price of the company (NASDAQ:BCRX) was down -4.43%, with a high of 4.49 during the day and the volume of BioCryst …
As a reminder, our operating expense guidance excludes equity base compensation due to the difficulty in the reliably …
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results ... as it is impacted by the volatility and price of the Company’s …
Shares of BioCryst Pharmaceuticals (BCRX) traded up 3.33% during trading on Tuesday, hitting $5.27. 587,268 shares of the company’s stock were exchanged. The stock’s 50-day moving average price is $5.63 and its 200-day moving …
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)‘s stock had its “buy” rating reissued by analysts at Noble Financial in a research report issued to clients and investors on Tuesday. BCRX has been the subject of a number of other research …
BioCryst Pharmaceuticals (BCRX) stock is on the rise after results from a trial of a drug to treat a rare immune disorder. The BioCryst trial showed that the company’s new drug, being called BCX4161, is effective against treating hereditary …
Positive trial results for the company's oral treatment for hereditary angioedema has BioCryst Pharmaceuticals stock up 34.6% today at $6.91, putting it near the top of the Nasdaq. BCRX stock has more than doubled over the past 12 …
Investors in BioCryst Pharmaceuticals, Inc. (BCRX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the May 19 th, 2017, $4 Call had some of the highest implied volatility of …
ZACKS3mon